Avalo Therapeutics, Inc. Common Stock

AVTXNASDAQ • USD
7.37 USD
↗ 0.00 (0.01%)🟢PRE MARKET (AS OF 09:02 AM EST)
🟢Market: OPEN

Shares of Avalo Therapeutics, Inc. Common Stock (AVTX) are trading at $7.37. Our models show a "Strong Sell" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place AVTX at a fair price relative to peers.

Technical & fundamental data as of Nov 16, 2026.

Open?$7.29
High?$7.74
Low?$7.20
Prev. Close?$7.37
Volume?416
Avg. Volume?2.6M
VWAP?$7.35
Rel. Volume?0.00x
Bid / Ask
Bid?$6.32 × 100
Ask?$9.85 × 100
Spread?$3.53
Midpoint?$8.09
Valuation & Ratios
Market Cap?426.2M
Shares Out?57.8M
Float?48.6M
Float %?90.6%
P/E Ratio?N/A
P/B Ratio?0.98
EPS?-$1.53
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Employees
33
Market Cap
448.7M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-11-13
Address
1500 LIBERTY RIDGE DRIVE
WAYNE, PA 19087
Phone: 410-522-8707
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
96
Momentum?
65
Short Sent.?
68
Piotroski F-Score?0/9Weak
Altman Z-Score?4.46Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?18.34%High
Short Interest?8.9M
Days to Cover?2.1
Free Float48.6M
Avg Daily Volume4.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?16.63Strong
Quick Ratio?16.63Strong
Cash Ratio?2.70Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.98CHEAP▾
P/S?
Peers
100
S&P
3
7,222.99HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.8CHEAP▾
EV/Sales?
Peers
100
S&P
3
6,121.49HIGH▾
Returns & Efficiency
ROE?
S&P
8
-20.3%WEAK▾
ROA?
S&P
3
-18.4%WEAK▾
Cash Flow & Enterprise
FCF?$-63466000
Enterprise Value?$361.2M
Fundamentals ratios updated end of day